Archive | November, 2023

Life Science Nation, Biocat, and Biotechgate Announce RESI Europe Barcelona 2024 – June 17th In-person | 18th & 19th Virtual

30 Nov

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Kendall Sq. Cambridge, MA, November 30th, 2023 — Life Science Nation (LSN), the visionary force behind the globally acclaimed Redefining Early Stage Investments (RESI) Conference Series, is thrilled to announce a strategic collaboration with Biocat, headquartered in Barcelona, Catalonia, Spain, and Biotechgate, Zurich, Switzerland. Biocat, a catalyzing organization dedicated to transforming the BioRegion of Catalonia into a premier life sciences and health innovation ecosystem in Europe, and Biotechgate, a pioneer in curating and marketing a global business development database tailored for the life science industry, join forces with LSN to bring the RESI global matching platform back to Europe.

The RESI Conference Series has been instrumental in connecting healthcare startups with capital investors, co-development partners, and licensing opportunities worldwide. LSN has a track record of assisting over 400 startups in raising over $5 billion through its investor database, entrepreneurial education, and RESI international partnering events. The LSN partner network, comprising ten categories of investors and licensing partners, actively seeks early-stage innovations in drugs, devices, diagnostics, and digital health for investment portfolio and product pipeline development.

The Power of RESI Partnering

The RESI Partnering platform is a dynamic tool designed to match attendees based on sector, indication, and development phase and is central to the RESI Conference Series. This innovative approach eliminates most ill-fitting meetings, ensuring startups engage with the right investors and licensing partners who align with their specific needs and goals. RESI partnering events run five times annually at life science centers worldwide. They facilitate fundraising CEOs and scientist-entrepreneurs to get out of their local region and into the international market, dramatically increasing the number of potential partners in their pipeline. Fundraising is a numbers game; a startup cannot succeed with one or two conferences yearly. LSN’s startups seek seed funding up to 2M, Series A, 2M-10M, and Series B, 10M-50M. As part of their global partnering campaign initiative, startup companies leverage RESI as a strategic launchpad to meet national and international investors and licensing partners.

“Biocat is unique in Europe because they get it; they understand that shining an international light on their startups and getting them into capital and licensing arrangements early builds the ecosystem’s future,” says Dennis Ford, CEO of Life Science Nation.

Robert Fabregat, CEO of Biocat, said, “LSN has developed a buy-side network that will bring tens of millions of Euros into the BioRegion. Biocat is confident that our rich life science technology ecosystem will capture the attention of global investors and licensing partners and enhance BioRegion’s global footprint.”

Patrik Frei, CEO of Biotechgate, stated, “The Catalan BioRegion, like many others in the European market, is not getting enough of the early-stage investor attention they deserve. Now, startups can attend RESI Europe Barcelona, meet LSN’s global partners, and plug into international RESI events in and outside Europe.”

About RESI Conference Series

RESI is a well-established go-to partnering event series for international scientist-entrepreneurs and fundraising CEOs. It offers a dynamic interactive format featuring one day of face-to-face meetings and two days of global virtual partnering. The RESI Conference Series spans North America, Europe, and Asia, receiving support from governmental agencies, regional international tech hubs, incubators, and accelerators. The 2024 RESI partnering events are scheduled as follows: RESI JPM in San Francisco on January 9th, RESI South Atlanta on March 25th, RESI Europe Barcelona on June 17th, RESI Boston on September 25th, and RESI Asia (location and partner TBD) in November.

About Life Science Nation (LSN)

Life Science Nation (LSN) created the globally recognized Redefining Early Stage Investments (RESI) Conference Series. LSN’s mission is to connect early-stage life science companies with investors and strategic partners, ultimately fostering innovation and driving advancements in the life sciences industry.

About Biocat

Biocat is a strategic stakeholder and catalyst for promoting, transforming and projecting the Catalan life sciences and health innovation ecosystem, known as the BioRegion of Catalonia. It was established in 2006 as a public-private foundation at the behest of the Government of Catalonia and the Barcelona City Council to identify the needs of the BioRegion and implement a strategy and action plan to maximize the economic and social impact of the sector.

About Biotechgate

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

Tech Hubs at RESI & Tech Hub Opportunities

27 Nov

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Startups affiliated with a tech hub such an incubator, accelerator, university, non-profit, or government agency are eligible for up to $600 off tickets to RESI JPM, January 9 – 11th, in San Francisco. To get access to a unique discount code, tech hubs or startups affiliated with tech hubs must reach out to Erika Wu at e.wu@lifesciencenation.com 

Tech hubs are also eligible to save 50% off all sponsorship levels at RESI. This is a great opportunity to showcase your startups’ technologies, host a workshop, be featured in LSN’s Next Phase and Tech Hub newsletters, and sell services at an exhibition booth. 

Don’t miss your chance to get access to: 

  1. Networking Opportunities  
  2. Access to New Technologies  
  3. Deal Flow Generation  
  4. Early Market Trends and Insights  
  5. Investor Engagement  
  6. Brand Visibility  
  7. Learning and Education from LSN staff and sponsor 

    Tech hubs currently registered for RESI JPM 2024Sign Up Here

RESI JPM 2024 will occur via a hybrid format, with January 9th being in-person at the Marine’s Memorial Hotel in San Francisco, and the 10th and 11th with virtual partnering only. We are expecting 500+ early-stage life science investors and 500+ startups at the upcoming RESI. Check out who’s currently registered

LSN Tagline Contest Winners Announced – The Power of Precision: Having a Clear and Concise Tagline, Not a Slogan

22 Nov

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the dynamic, highly competitive life science arena, a startup company must have its story straight and act together. Understanding that effective communication is the crux of a successful investor and licensing partner campaign. Life science startup companies face the unique challenge of distilling complex ideas into digestible messages for their target audience. In this context, a clear and concise tagline and elevator pitch seamlessly integrated into the one-page data sheet, two-page executive summary, and 10-12-page pitch deck cannot be underestimated. The tagline and elevator pitch you develop for your startup are a potent tool, serving as the linchpin for all your present and future marketing endeavors. The tagline and elevator pitch anchor all your branding and messaging. These two entities are not slogans, they should be viewed in the context that if the right person read them, they would want to have a meeting with you.

LSN Has Developed a Process for the Continuity of Messaging

tagline

Life science startups often deal with intricate scientific concepts and advanced technologies. Communicating these complexities to a target audience, including investors, potential collaborators, and licensing partners, requires a delicate balance. A concise tagline is a beacon of clarity, distilling the company’s core purpose and value proposition into a few impactful words. This clarity is essential for effective communication and builds trust and credibility. A good tagline is hard to craft but easy to identify, requiring multiple iterations. Companies will frequently end on a tagline that is partway there, not realizing the difference that more work can make. This is the difference between a tagline such as ‘novel robotic platform to treat cancer’ and ‘Advancing Localized Cancer Interventions with Self-driving Robotic Platform’ – one tagline seems to provide a good amount of detail, while the other is clearly much more detailed but still concise. A well-crafted tagline remains an invaluable asset in the arsenal of marketing materials for startups striving to make a lasting impact.

Life Science Nation announced a Tagline Competition Contest. The top three taglines to receive complimentary registrations to our upcoming partnering conference, RESI JPM in San Francisco at the Marine’s Memorial Club & Hotel on January 9. The staff at LSN evaluated each submission based on clarity, level of detail, and conciseness when considering the top three. Thank you to the companies that applied. LSN evaluated close to 100 submissions. The winners are:

Tagline Competition Contest Winners
Flexperc Medical
Advancing Localized Cancer Interventions with Self-driving Robotic Platform
Nesa Medtech 
Transform women’s health by developing a scarless, image-guided surgical solution to treat uterine fibroids.
Inherent Biosciences 
Pioneering Epigenetic Diagnostics in Reproductive Health

Congratulations to the winners! We look forward to seeing you at RESI JPM!

RESI-SF-2024-Banner-1100

LSN’s Asia Roadshow Part 1: Entrepreneurial Educational Bootcamps in Hong Kong and Singapore

16 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN

claire

During October and November, LSN’s team traveled to Asia to meet regional partners, explore RESI Asia’s potential,  and, most importantly, deliver LSN Entrepreneurial Bootcamps to Hong Kong region startups in collaboration with Hong Kong Science and Technology Park (HKSTP) and Life Science Incubator.

LSN partnered up with the HKSTP team and tailored the program to fit the needs of about 75 startup, primarily members of HKSTP’s Incubio program, focusing on tactical advice and actionable steps for launching your company in the life science and healthcare industry and how to execute a capital fundraising and licensing partner campaign on a global scale. The two-day boot camp from October 19 to 20th attracted attendees from various backgrounds, including university researchers, scientists, physicians, and all who are actively building a new generation of startup companies. The team discussed the value of delivering a compelling story to potential partners that reveals who the founder and team are and what factors brought them together. The LSN team provided interactive exercises to encourage attendees to enhance their “problem/solution/market” pitch decks with a compelling narrative and create taglines and elevator pitches that net out the value of their product while making it easy to understand without dumbing down the message.

On the second day of the boot camp, the LSN team met one-on-one with selected companies to provide consultations on their current fundraising materials, partnering strategies, and critical business development objectives. The great technologies that we were able to review during these two days were a testament to the impressive scientific research talent in Hong Kong. The LSN platform matches global startups with international investors and licensing partners who seek them by using the LSN investor and licensing partner database or attending one of the RESI conferences LSN holds worldwide. Most investors and licensing partners are global and mainly focus on the team and technology rather than their location. Bringing LSN’s global perspective that partnering is fundamentally a numbers game, and you need to leave your region and meet the players that fit your stage of development and product is the straightest line to successful partnering.

Next up was the Life Science Incubator in Singapore on October 24th. Once again, we meet with dynamic entrepreneurs who are creating new products that will significantly impact life science. The boot camp was designed to be more hands-on with one-on-one interaction where the LSN team shared insights based on our collective experiences working with clients and addressed questions about how to find, vet, and approach the investors and licensing partners that fit your startup. The boot camp culminated with attendees getting practice doing elevator pitches, followed by the LSN team providing feedback and coaching.

In addition to the boot camp, we attended the Asia Health and Life Sciences Innovation and Cooperation Summit (AHLSICS) organized by Ask Health Asia. The summit featured an impressive lineup of senior executives from key industry players, government organizations, and investment firms through a series of thoughtfully curated and highly informative panels and keynote presentations, focusing on the landscape and environment of innovation and market opportunities in Asia.

It was a pleasure for the LSN team to meet with many life science healthcare innovators in Hong Kong and Singapore, along with several key players and government organizations. We were highly impressed by the vibrant startup ecosystem, cutting-edge infrastructures, and the active role of the governments in providing substantial, practical support for tech transfer, startup funding, and R&D. The trip was immensely fruitful in helping LSN map the landscape of Hong Kong and Singapore’s life science and healthcare ecosystem, solidifying LSN’s position to support local innovators to expand their business to a global scale. We want to extend our gratitude to those who met with us or hosted us during the trip, and we look forward to collaborating more in the future.

20231019_103429000_iOS

LSN’s The Entrepeniual Educational series, which features 16 novel entrepreneurial courses, is designed for entrepreneurs who are starting to plan for their fundraising and licensing partner search. The educational programs focus on getting your company’s marketing collateral ready, followed by how to manage an efficient fundraising campaign to maximize the probability of getting a second meeting, which can greatly determine an early-stage entity’s success when moving from their regional environment to the global competitive landscape. If you have any questions about hosting an LSN education course please contact Karen Deyo, VP of Product, Israel BD, LSN.

RESI-SF-2024-Banner-1100

Save $300 and Meet 500+ Investors at RESI JPM – Early Bird Rates End Tomorrow

16 Nov

By Cameron Hurlburt, Director of Business Development, LSN

Friday is the last day to register for RESI JPM this January at the Early Bird Pricing Rate. The Conference will occur via a hybrid format, with January 9 being in-person at the Marines’ Memorial Club and Hotel and the 10-11 occurring by way of Virtual Partnering. Our Early Bird Registration options are as follows:

  Standard
3-day
In-person
1-day
Virtual
2-day
Audience Access Pass
STARTUP $1,995
$2,295
$1,595
$1,895
$995
$1,195
$595
(Fixed rate)
SERVICE PROVIDER $2,495
$2,795
$2,095
$2,395
 $1,295
$1,495
EXHIBITOR $4,990 $5,590 Includes Two 3-Day Standard Tickets (Value: $5,590) and an Exhibition Table (January 9)
View RESI Sponsorship Brochure
TECH HUB & CONSTITUENTS $1,695
(Fixed rate)
$1,295
(Fixed rate)
$895
(Fixed rate)
Contact us to discuss further.

Register-now-button-new

Also, the slots to participate in the Innovator’s Pitch Challenge (IPC) at RESI San Francisco this January are filling up fast and the deadline to apply is Wednesday, November 22! If you’re early-stage and raising money, you DON’T want to miss the opportunity to participate in this pitching challenge. It’s the most important week in life sciences partnering, and RESI is the only place you can pitch before a live audience to a panel of investors that are focused on your sector which includes Therapeutics, MedTech, Diagnostics, Digital Health, and R&D Services.

Apply-for-the-IPC

Plus, you can meet with 500+ early-stage life science investors and strategic partners who will attend RESI over 3 days of partnering, one in person and two in digital.

Get the visibility you need for startup company at RESI during JPM healthcare conference week. Let me know if you have any questions. See you in San Francisco!

RESI-SF-2024-Banner-1100

Gliachem’s Innovator’s Pitch Challenge Success at RESI

16 Nov
Vanessa-WilliamsonVanessa Williamson Interview with Vanessa Williamson, Entrepreneur-in-Residence/CEO at Gliachem

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): Please introduce us to Gliachem and the company’s technology.

Vanessa Williamson (VW): Gliachem is a pre-clinical stage company developing small molecule therapeutics for rare and neurological diseases being spun out from the University Health Network (UHN) in Toronto, Canada. We have a first-in-class neurology drug development program with a unique mechanism of action and are targeting Rett Syndrome as our initial clinical indication.

Rett Syndrome is a rare, x-linked neurological disorder that affects how the brain develops, typically manifesting in females at 18-36 months. Its symptoms are highly debilitating and include intractable motor and cognitive disabilities, breathing issues, and seizures. Lifelong caregiver support is required, and patient lifespan is often reduced. Limited treatment options exist, and the only approved drug, Trofinetide, shows small effect size and tolerability issues, leaving significant room for improvement. With 350,000 Rett patients worldwide, including 34,000 in major markets, there is the chance for blockbuster success.

We are currently in the advanced hit to lead stage. We have strong genetic target validation for a novel Rett target, target PD assays developed and qualified to support lead candidate identification and have developed 3 distinct chemical series (NCEs), each demonstrating potency, selectivity and drug-like properties.

CD: Tell us about Gliachem’s team.

VW: Gliachem is in the process of incorporation, which will be complete by the end of 2023. Our team is currently our scientific co-founders – Dr. James Eubanks and Dr. Mark Reed – and myself as CEO. Over the next few months, we will be expanding the leadership team.

The technology originated in the lab of Dr. Eubanks at UHN. Dr. Eubanks is a neurodevelopment and molecular genetics expert with over 30 years of experience in academic research, including translational development. He is also a well-recognized KOL in Rett Syndrome. At UHN, he is a Senior Scientist and Research Division Head for Experimental and Translational Neuroscience at the Krembil Research Institute.

Dr. Reed is an accomplished medicinal chemist and expert in CNS drug discovery with over 20 years of experience in academia, biotech, and large pharma. He is currently the Director of the Center for Medicinal Chemistry and Drug Discovery at UHN, as well as co-founder and CSO of Treventis Corporation, a biotech start-up focused on protein misfolding related specifically to Alzheimer’s, who recently partnered their lead program with Takeda for $350M.

I have executive experience in the life sciences sector, including the scale-up and commercialization of small molecule therapeutics and diagnostics. Prior to Gliachem, I’ve most recently held VP Corporate Development roles in the diagnostics space, focusing on business and partnership development, sales and marketing, as well as M&A and fundraising.

CD: This was Gliachem’s first time at RESI. How did you initially learn about the conference and what did you think of the RESI experience?

VW: In a word, RESI was AMAZING. We learned about the conference from the Commercialization Office at UHN, who also supported our participation. We did the in-person partnering, as well as the Innovators Pitch Challenge (IPC). RESI curated a fantastic list of investor attendees, and the entire event was so smooth and well organized. The details about the investors that you could access through the partnering platform, especially if you elected the Premiere Mandate, was second to none. That enabled us to strategically target investors, making the whole meeting highly productive.

CD: What stage of fundraising is Gliachem in and what are your goals in 2024?

VW: RESI was the soft launch of our fundraising. We had the opportunity to meet with many early-stage investors from around the world and test both the market and our business plan. We had some very engaging meetings and positive feedback, and are ready to get into deeper discussions. We are raising a $3.2M CAD seed round, which will enable us to complete our hit to lead activities, identify an advanced lead, complete our proof of concept in a Rett animal model and initiate lead optimization. We are looking for strategic investors, who will not only provide financing, but who will also support us in this very exciting stage of early growth.

CD: Congratulations on your second-place finish at RESI Boston September Innovator’s Pitch Challenge (IPC)! What do you think was the key to your success at RESI September?

VW: Thank you! We are so proud of this accomplishment!

Aside from our team and technology, it absolutely was the amount of time we spent preparing. A 4-minute pitch is not easy. There is an opportunity to add a bunch more content than you would with just a standard elevator pitch, but you can’t overload. Coming up with a succinct message that focused on the problem, solution, differentiation and market opportunity was key. As tempting as it was to get deep into the science, we focused on the business opportunity.

The LSN and RESI resources were also invaluable. We attended the prep session you offered and followed the recommendations with respect to focus.

Preparation also applies to the investor meetings. Research the investors. Reach out to the right ones with a tailored and succinct message. And be persistent. Needless to say, many of my best meetings did not come from immediate replies to my initial message.

CD: What advice would you like to give to fellow entrepreneurs about RESI conferences?

VW: In short, do it! It was an invaluable experience. Take advantage of the IPC (including the poster area) as it does enable another level of exposure that you wouldn’t usually get. The judges also provided written feedback which we have used as we continue to evolve our pitch. Finally – prepare, prepare, prepare. Have a plan. There is a lot going on in a really short time, and to maximize the opportunities you need to have a plan. That said, don’t be constrained by your planning and be open to going with the flow. The serendipitous connections for me were just as valuable as the targeted ones.

RESI-SF-2024-Banner-1100

Hot Investor Mandate: Life Sciences-Focused Venture Fund Invests Up to $25M in Therapeutics Targeting Oncology, Metabolic Disorders, and More With China Market Potential

16 Nov

A sector-exclusive life sciences venture and growth equity fund is focused on Asia, particularly China. The firm has offices in China, Hong Kong, and the US. The firm has multiple billion AUM, is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. With both USD and RMB funds, the firm focuses on China but also considers opportunities from USA.In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.